Compounding Pharmacy · Franklin, TN · 503A

DCA Pharmacy Review

DCA Pharmacy is one of the largest 503A compounding pharmacies in Tennessee, located in Franklin, TN, and licensed to ship to 48 states. Specializes in bio-identical hormone replacement, topical pain management, scar therapy, pellet therapy, and sterile compounding. Named in a 2023 Novo Nordisk lawsuit over compounded semaglutide; the case was voluntarily dismissed.

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more

503AState pharmacy license503A
Location: Franklin, TN
States licensed: 49
6.0
Weight Loss Rankings Score
out of 10

About this pharmacy

DCA Pharmacy is one of the largest 503A compounding pharmacies in Tennessee, located in Franklin, TN, and licensed to ship to 48 states. Specializes in bio-identical hormone replacement, topical pain management, scar therapy, pellet therapy, and sterile compounding. Named in a 2023 Novo Nordisk lawsuit over compounded semaglutide; the case was voluntarily dismissed.

Certifications & Compliance

All sterile compounding pharmacies in the United States are required to follow United States Pharmacopeia General Chapter <797> sterile compounding standards[4], with finished preparations evaluated against USP <71> sterility testing[5] and USP <85> bacterial endotoxin testing[6] as appropriate for the product type.

State pharmacy license
Additional certification disclosed by the pharmacy.
503A
Additional certification disclosed by the pharmacy.

Drugs Produced

Compounding pharmacies' ability to produce semaglutide or tirzepatide depends on the FDA Drug Shortage List status for each reference product; compounding eligibility can change when a drug moves on or off the shortage list[7].

Yes
Semaglutide
Compounded semaglutide produced
Yes
Tirzepatide
Compounded tirzepatide produced

States Licensed (49)

ALAKAZARCACOCTDEFLGAHIIDILINIAKSKYLAMEMDMAMIMNMSMOMTNENVNHNJNMNYNCNDOHOKORPARISDTNTXUTVTVAWAWVWIWY

Regulatory Actions

2023-XX-XX
Named in Novo Nordisk Inc. v. DCA Pharmacy, Case No. 3:23-cv-00668 (M.D. Tenn. 2023), alleging trademark infringement on compounded semaglutide marketing. Novo voluntarily dismissed the case; DCA remains operationally active.

Weight Loss Rankings Score Breakdown

Accreditation & Compliance6/10
Regulatory Standing5/10
State Coverage10/10
GLP-1 Production10/10
Track Record5/10

Scores are independently researched. See our methodology for details.

Medium confidence · Last verified 2026-05-23 via pharmacy-directory-cross-state-audit-2026-05-23 · How we verify provider data

Frequently Asked Questions

Glossary references

Key terms in this article, linked to their canonical definitions.

Sources & methodology — as of May 2026
  1. 1.FDA — Compounding and the 503A Pharmacy FrameworkU.S. Food & Drug Administration.
  2. 2.FDA — 503B Outsourcing Facility Registration and RequirementsU.S. Food & Drug Administration.
  3. 3.PCAB — Pharmacy Compounding Accreditation Board StandardsAccreditation Commission for Health Care (ACHC) / PCAB.
  4. 4.USP General Chapter <797> — Pharmaceutical Compounding: Sterile PreparationsUnited States Pharmacopeia.
  5. 5.USP General Chapter <71> — Sterility TestsUnited States Pharmacopeia.
  6. 6.USP General Chapter <85> — Bacterial Endotoxins TestUnited States Pharmacopeia.
  7. 7.FDA — Drug Shortages Database (current shortage listings)U.S. Food & Drug Administration.